Member Posts > Cardiol Therapeutics: CRD-38 - A Subcutaneous Cannabidiol Solution for Advanced Heart Failure Therapy
Innovating Heart Failure Treatment with CRD-38
Heart failure affects millions worldwide, yet existing treatments focus primarily on symptom management rather than modifying disease progression. CRD-38, a subcutaneous cannabidiol therapy, offers a targeted approach to addressing the inflammatory mechanisms underlying heart failure.
Why Subcutaneous CBD?
✔ Greater bioavailability, ensuring better drug efficacy.
✔ Sustained plasma drug levels, reducing therapeutic inconsistencies.
✔ Potential for lower dosing frequency, minimizing treatment burden.
Key Findings from Preclinical Studies
📌 Significant reductions in BNP, a marker of heart failure severity.
📌 Improved fat metabolism, alleviating cardiac stress.
📌 Cardioprotective benefits, supporting CRD-38's potential as a transformative therapy.
The Road to Clinical Development
✔ Pharmacokinetic testing for optimal dosing.
✔ Preclinical safety assessments in progress.
✔ Preparing regulatory filings for first-in-human trials.

🌐 Discover More About This Treatment
#HeartHealth #CardiolTherapeutics #MedicalBreakthrough #CRD38 #CardiacCare #CardiolRx